There is a growing evidence that oral poly (ADP-ribose) polymerase inhibitor, olaparib impedes the growth of ATM null or ATM mutant lymphoma cells in vitro and in vivo by instigating the accumulation of intolerable levels of DNA damage in cycling tumor cells [39], [40]. This evidence concerns the gene ATM and neoplasm.